Ozanimod

In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. ^[1]

In vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses clinical symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits clinical and histological disease scores. In a Naïve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. ^[1]

• In vitro pharmacology assays

  Cell signaling assays used the LiveBLAzer-FRET B/G assay to detect cAMP (S1P1R) or β-arrestin signaling (S1P4R). Assays are performed in 384-well plates in triplicate according to manufacturer directions. Compound stocks are stored at 10 mM in 100% DMSO at -80°C, and initially diluted 1:10 with 20% (2-hydoxypropyl)-β-cyclodextrin. A 10-point dose response curve is generated at 40-times the final assay concentration in 10 mM Hepes pH 7.4, containing 0.1% Pluronic F-127. For the S1P1R assay, 80 μM forskolin is included in the diluent. Briefly, 10⁴ cells/well are incubated with a dose response of ligand at 37°C for 4 hrs. CC4-AM substrate and probenecid are added and incubated at 37°C for a further 2 hrs and analyzed with a SpectramaxM5. For S1P1R cAMP assays, data is normalized to the maximum fluorescence generated by 2 μM forskolin. For GTPγS binding assays, 1-5μg/well of membrane protein is incubated with 10 μM GDP, 100-500 μg/well Wheat Germ Agglutinin PVT SPA beads in 50 mM HEPES, 100 mM NaCl, 10 mM MgCl₂, 20 μg/ml saponin and 0.1% fatty acid free BSA for 15 minutes in 96-well plates. After the addition of compound and 200 pM GTP [35S] 1250Ci/mmol), the plates are incubated for 120 minutes and centrifuged at 300g for 5 minutes. Radioactivity is detected with a TopCount Instrument. All data is fit with a four parameter variable slope non-linear regression (GraphPad Prism) to generate half-maximal effective concentration (EC50) and maximum efficacy relative to S1P.

• Cell lines

  HEK293T cells

• Concentrations

  1 μM

• Incubation Time

  1 h

• Method

  Cells expressing S1P1 receptors were incubated with vehicle control or 1 μM RPC1063 for 1 h.

• Animal Models

  MOG-induced EAE model in C57Bl6 mice, TNBS model of inflammatory bowel disease in male Sprague Dawley rats, and Na飗e CD4+CD45Rbhi T cell adoptive transfer model in SCID mice

• Dosages

  0.1-3 mg/kg

• Administration

  p.o.